Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 cefepime-taniborbactam versus meropenem for ventilated hospital-acquired bacterial pneumonia
MOH_2023-08-17_012879Phase 3Not yet recruiting
- Sponsor
- Venatorx Pharmaceuticals
- Start
- Jun 2023
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) comparing Cefepime-taniborbactam with Meropenem comparator (2 arms). Primary endpoint: All-cause mortality at Day 14. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
cefepime + taniborbactammeropenem
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on MOH_2023-08-17_012879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-17_012879.